Study of Exenatide Once-Weekly Suspension in Chinese Patients with Type 2 Diabetes Mellitus

Study identifier:D5553C00008

ClinicalTrials.gov identifier:NCT04001231

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase 1, Open-Label Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety, and Tolerability of Exenatide Once-Weekly Suspension in Chinese Patients with Type 2 Diabetes Mellitus

Medical condition

Type 2 Diabetes

Phase

Phase 1

Healthy volunteers

No

Study drug

Exenatide Once-Weekly Suspension

Sex

All

Actual Enrollment

0

Study type

Interventional

Age

20 Years - 75 Years

Date

Study Start Date: 30 Jun 2020
Estimated Primary Completion Date: 02 Jul 2021
Estimated Study Completion Date: 02 Jul 2021

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 May 2020 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria